This activity is expired and is no longer available for CME credit.


New Options in Diabetic Retinopathy: Let the Data Be Your Guide

Author(s)/Faculty: Peter K. Kaiser, MD; Darius M. Moshfeghi, MD
Release Date: 4/9/2020Expiration Date: 4/8/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: LectureProvider:
Early diagnosis and prompt treatment of diabetic retinopathy (DR) has been shown to effectively prevent vision loss. Until recently, panretinal photocoagulation was the primary management approach for DR. However, clinical trial data from pinnacle studies utilizing anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular edema have demonstrated that anti-VEGF therapy is also an effective treatment option for patients with DR. Specific data on the optimal use of anti-VEGF agents to treat DR have emerged from both initial studies establishing the effectiveness of anti-VEGF in this setting and subsequent clinical trials. In this CME activity, experts in the field will evaluate new findings pertaining to the optimization of treatment dosing and management of patients with DR, compare treatment protocols for proliferative versus nonproliferative DR, and assess treatment regimens for their ability to achieve regression of DR.